EU drug regulator OKs Novartis' meningitis B shot

Europe's top drug regulator has recommended approval for the first vaccine against meningitis B, made by Novartis AG.

There are five types of bacterial meningitis. While vaccines exist to protect against the other four, none has previously been licensed for type B meningitis. In Europe, type B is the most common, causing 3,000 to 5,000 cases every year.

Meningitis mainly affects infants and children. It kills about 8 percent of patients and leaves others with lifelong consequences such as brain damage.

In a statement on Friday, Andrin Oswald of Novartis said he is "proud of the major advance" the company has made in developing its vaccine Bexsero. It is aimed at children over two months of age, and Novartis is hoping countries will include the shot among the routine ones for childhood diseases such as measles.

Novartis said the immunization has had side effects such as fever and redness at the injection site.

Recommendations from the European Medicines Agency are usually adopted by the European Commission. Novartis also is seeking to test the vaccine in the U.S.

0 shares

Related Stories

Sanofi gets expanded meningitis vaccine approval

date Apr 25, 2011

(AP) -- Sanofi Pasteur, the vaccines division of Sanofi-Aventis, said Monday the Food and Drug Administration approved the company's bacterial meningitis vaccine Menactra for children between the ages of 9 months and 23 months.

FDA expands meningitis vaccine approval

date Oct 22, 2007

The U.S. Food and Drug Administration has expanded approval for the use of Menactra, a bacterial meningitis vaccine, to children ages 2 to 10.

Meningitis B type vaccine available soon

date Jan 20, 2012

(Medical Xpress) -- Researchers in Chile have successfully tested a vaccine against meningococcus B, a strain of bacteria that causes meningococcal diseases, including one of the commonest forms of meningitis, a disease in ...

A new strategy for developing meningitis vaccines

date May 24, 2012

Bacterial meningitis is an infection of the meninges, the protective membrane that covers the spinal cord and brain. Children, elderly patients and immunocompromised patients are at a higher risk for the development of severe ...

Recommended for you

US aims to cut antibiotic use

date Mar 27, 2015

US President Barack Obama on Friday rolled out plans to cut inappropriate antibiotic use by half, in an effort to tackle drug resistance.

Questions over value of new antibiotics to tackle resistance

date Mar 26, 2015

In the first installment of a new series, Peter Doshi, Assistant Professor at the University of Maryland School of Pharmacy and Associate Editor at The BMJ, asks why authorities are approving drugs with little evidence they d ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.